Self-Sampling Shows Test Agreement - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

  • By

  • Andrea Surnit

  • July 8, 2026

  • 5 min

Share

Objective:

To evaluate the agreement between self-collected cervical specimens and clinician-collected samples for cytology, high-risk HPV testing, and STI-related molecular testing.

Approach:
  • Study Design: A prospective paired study involving 520 women undergoing routine cervical cancer screening at a gynecologic clinic in Korea, comparing self-sampling with clinician-collected samples.
  • Self-Sampling Procedure: Participants used the Earlypap device for self-sampling, followed by clinician collection during the same visit.
  • Testing Methods: Samples were analyzed for liquid-based cytology, high-risk HPV testing, and STI-related molecular testing.
  • Participant Feedback: Participants rated the self-sampling procedure and expressed preferences for future use.
Key Findings:
  • Overall agreement: 91.7% for cytology, 95.4% for high-risk HPV testing, and 97.0% for STI-related molecular testing.
  • Self-sampling was successfully completed on the first attempt by 98.5% of participants.
  • 92.1% of participants preferred self-sampling over clinician collection.
  • Abnormal cytology was highest among women younger than 30 years.
  • Histologic follow-up was limited and not systematic for all participants.
Interpretation:

Limitations:
  • Lack of systematic histologic confirmation for all participants with abnormal results.
  • Single-center study may limit generalizability.
  • Modest sample size may not establish definitive equivalence.
  • Reliance on a single liquid-based cytology platform.
Conclusion:

Sources:

Original Source(s)

Self-Sampling Shows Test Agreement

  • by Andrea Surnit

  • July 8, 2026

Related Content

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Misdiagnosis Common in Parkinsonian Disorders

Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.